Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 2
2007 2
2008 1
2010 1
2012 2
2013 4
2014 3
2015 1
2016 2
2017 4
2018 4
2019 7
2020 13
2021 12
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primary Amyloidosis"
Page 1
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. San-Miguel J, et al. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272512 Clinical Trial.
METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of …
METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myel …
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible. Patients were randomly assigned (3:2) to isatuximab plus carfilzomib-dexam …
Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy …
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. Shah BD, et al. Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097852 Clinical Trial.
BACKGROUND: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies. …
BACKGROUND: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients …
Management of AL amyloidosis in 2020.
Palladini G, Milani P, Merlini G. Palladini G, et al. Blood. 2020 Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913. Blood. 2020. PMID: 33270858 Free article. Review.
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils. Organ involvement determines the clinical …
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal l …
Comprehensive Review of AL amyloidosis: some practical recommendations.
Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Al Hamed R, et al. Blood Cancer J. 2021 May 18;11(5):97. doi: 10.1038/s41408-021-00486-4. Blood Cancer J. 2021. PMID: 34006856 Free PMC article. Review.
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (F …
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the …
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary …
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the …
Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K, Phelps MA. Kim K, et al. Clin Pharmacokinet. 2023 Jun;62(6):789-806. doi: 10.1007/s40262-023-01240-8. Epub 2023 May 2. Clin Pharmacokinet. 2023. PMID: 37129750 Review.
Daratumumab is a fully human, monoclonal immunoglobulin G1 and a first-in-class CD38-targeting drug approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory and newly diagnosed multiple myeloma or newly diagnosed ligh …
Daratumumab is a fully human, monoclonal immunoglobulin G1 and a first-in-class CD38-targeting drug approved by the US Food and Drug …
Immunotherapy in AL Amyloidosis.
Zhang Y, Comenzo RL. Zhang Y, et al. Curr Treat Options Oncol. 2022 Jul;23(7):1059-1071. doi: 10.1007/s11864-021-00922-4. Epub 2022 May 30. Curr Treat Options Oncol. 2022. PMID: 35635625 Review.
Light-chain amyloidosis is a rare disorder where a small clone of plasma cells is producing excess toxic light chains that deposit in various organs and cause dysfunction. Cardiac involvement is a major determinant of survival and rapid reduction of light …
Light-chain amyloidosis is a rare disorder where a small clone of plasma cells is producing excess toxic light chains t …
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.
Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Das S, et al. Curr Oncol. 2023 Oct 31;30(11):9627-9633. doi: 10.3390/curroncol30110697. Curr Oncol. 2023. PMID: 37999117 Free PMC article.
While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patients with AL amyloidosis have been excluded from trials with these agents due to concerns of underlying autonomic, cardiac, and renal dy …
While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patient …
Advances in the treatment of light chain amyloidosis.
Palladini G, Milani P. Palladini G, et al. Curr Opin Oncol. 2022 Nov 1;34(6):748-756. doi: 10.1097/CCO.0000000000000881. Epub 2022 Aug 4. Curr Opin Oncol. 2022. PMID: 35943427 Review.
PURPOSE OF REVIEW: After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evidence-based medicine, with three recently published randomized clinical trials, a regimen (daratumumab, cyclophosphamide, bort …
PURPOSE OF REVIEW: After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evi …
68 results